Every woman has a one in 87 chance of getting ovarian cancer in her lifetime, and one in 130 will die from it. The symptoms ...

A study led by Roswell Park Comprehensive Cancer Center provides new insight into the complex interactions of the ...

Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001Vertical integration of major ...

For those with recurrent ovarian cancer, there is now a chemo that’s targeted, attacking specifically the cancer cells instead of the whole body. Then, when it comes time for surgery ...

GSK’s FIRST-ENGOT-OV44 phase III clinical trial of Zejula and Jemperl in first line advanced ovarian cancer meets primary endpoint: London Saturday, December 21, 2024, 09:00 Hrs ...

Rucaparib Maintenance Improves Long-Term Outcomes in Ovarian Cancer Rucaparib maintenance after first-line chemotherapy and ...

The complex interactions of the tumor–immune–gut axis can shape responses to immunotherapy in ovarian cancer, emphasizing the ...

First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the ...

Researchers have discovered how chemotherapy can change tumors, making them more vulnerable to new types of treatments. These ...

Implementing an individualized starting dose (ISD) of niraparib (Zejula; GSK) reduced severe hematologic adverse event (AE) ...